Pfizer ( PFE) is the top seller of pharmaceuticals in the U.S. and the world, but there's a drawback to its massive size and scale -- a pronounced lack of efficiency. For many years, Pfizer has been about big, from making giant acquisitions like Warner-Lambert and Pharmacia to marketing Lipitor, the world's best-selling drug. Now it's time for another big move, only this time it's a downsizing. On Monday, investors will learn just how many jobs management has decided to cut in order to better control the company's costs and eliminate operational excess. The scope of the payroll reduction has been a source of Wall Street speculation ever since Jeffrey Kindler, the CEO and chairman, said in October that all operations were under review . Sales positions overseas and manufacturing jobs are cited by analysts as the most logical targets that might save an extra $1 billion to $2 billion a year. Already, the number of manufacturing plants Pfizer runs has dropped to 61 from 93 since the end of 2003. And two months ago, Kindler said 20%, or approximately 2,200 members, of the U.S. sales force would lose their jobs . The company characterized the move as an "initial step" in restructuring. The next step will be revealed as Pfizer issues fourth-quarter and full-year 2006 results. The Wall Street consensus calls for earnings of 42 cents a share, excluding one-time items, for the fourth quarter on sales of $12.2 billion.